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Abstract 17 
A new type of self-assembled polyelectrolyte complex nanocarrier composed of chondroitin 18 
(CHON) and protamine (PROT) was designed and the ability of the carriers to bind salmon 19 
calcitonin (sCT) was examined. The response of sCT-loaded CHON/PROT NPs to a change in 20 
the properties of the liquid medium, e.g. its pH, composition or ionic strength was studied and in 21 
vitro peptide release assessed. The biocompatibility of the NPs was evaluated in Caco-2 cells.  22 
CHON/PROT NPs were successfully obtained with properties that were dependent on the 23 
concentration of the polyelectrolytes and their mixing ratio. X-ray diffraction determined the 24 
amorphous nature of the negatively charged NPs, while those with the positive surface potential 25 
were semi-crystalline. sCT was efficiently associated with the nanocarriers (98-100%) and a 26 
notably high drug loading (13-38%) was achieved. The particles had negative zeta potential 27 
values and were homogenously dispersed with sizes between 60 and 250 nm. CHON/PROT NPs 28 
released less than 10% of the total loaded peptide in the first hour of the in vitro release studies. 29 
The enthalpy of the decomposition exotherm correlated with the amount of sCT remaining in NPs 30 
after the release experiments. The composition of medium and its ionic strength were found to 31 
have a considerable influence on the release of sCT from CHON/PROT NPs. Complexation to 32 
CHON markedly reduced the toxic effects exerted by PROT and the NPs were compatible and 33 
well tolerated by Caco-2 cells.  34 
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List of abbreviations: 39 
AB - acetate buffer 40 
AE - association efficiency 41 
ANOVA - one-way analysis of variance  42 
Arg – arginine 43 
ATR-FTIR - attenuated total reflectance Fourier transform infrared spectroscopy 44 
CHON - chondroitin 45 
COM1 - complex 1, composition: chondroitin/protamine mass mixing ratio=3.1, final chondroitin 46 
concentration=0.7 mg/ml 47 
COM2 - complex 2, composition: chondroitin/protamine mass mixing ratio=3.1, final chondroitin 48 
concentration=1.4 mg/ml 49 
COM3 - complex 3, composition: chondroitin/protamine mass mixing ratio=12.5, final 50 
chondroitin concentration=1.4 mg/ml 51 
COM4 - complex 4, composition: chondroitin/protamine mass mixing ratio=3.1, final chondroitin 52 
concentration=2.1 mg/ml  53 
COM5 - complex 5, composition: chondroitin/protamine mass mixing ratio=5, final chondroitin 54 
concentration=3.6 mg/ml 55 
COM6 - complex 6, composition: chondroitin/protamine mass mixing ratio=0.2, final chondroitin 56 
concentration=0.16 mg/ml, positively charged nanoparticles 57 
dH – enthalpy of process 58 
DL - drug loading 59 
DSC - differential scanning calorimetry  60 
FBS - fetal bovine serum 61 
HA - hyaluronic acid 62 
HPLC – high performance liquid chromatography 63 
kDa – kilodalton 64 
4 
kV – kilovolt 65 
mA – milliampere 66 
MEM - Eagle’s Minimal Essential Medium  67 
MMR - mass mixing ratio 68 
MPS – mean particle size 69 
MTS - 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 70 
MWCO – molecular weight cut-off 71 
NP – nanoparticle 72 
PBS - phosphate-buffered saline  73 
PDI - polydispersity index  74 
PROT – protamine 75 
PXRD - powder X-ray diffraction 76 
sCT - salmon calcitonin 77 
Tg - glass transition 78 
TR – transmittance 79 
ZP - zeta potential  80 
 81 
1. Introduction 82 
Considerable efforts have been dedicated towards incorporation of bioactive ingredients into 83 
nanoparticles (NPs) composed of biodegradable polymers (Hamidi et al., 2008). There are a 84 
considerable number of polymers and techniques that are used to produce NPs, which allows a 85 
broad differentiation of their internal and external structures as well as composition and biological 86 
properties. The choice of the nanoparticle manufacturing method is influenced by the solubility of 87 
the active compound to be associated/complexed with the NPs as well as the solubility, chemical 88 
structure, characteristic chemical groups, molecular weight and crystallinity/amorphicity of the 89 
polymer (des Rieux et al., 2006). The most commonly used polymers are polyesters (e.g. 90 
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poly(lactic acid) and poly(lactic-co-glycolic acid)), either alone or in combination with other 91 
polymers (des Rieux et al., 2006).  However, the limitation of biodegradable water-insoluble 92 
polymers is that they are mostly hydrophobic, whereas nucleic acids, many peptides and proteins, 93 
which are recognised to have a great potential in therapeutics, are hydrophilic. This leads to 94 
difficulties for the drug to be efficiently encapsulated (Sundar et al., 2010). Hence, the preparation 95 
of NPs with the employment of more hydrophilic and naturally occurring polymers has been 96 
explored. Among polymeric NPs, those composed of polyelectrolytes (polyelectrolyte complex 97 
NPs or nanoplexes) attract particular attention e.g. because of their water soluble character 98 
(Hartig et al., 2007). Amongst cationic polymers used in the formation of nanoplexes, undoubtedly 99 
chitosan is the most extensively investigated (Boateng et al., 2014). Recently, other polycations 100 
have also been employed in the formation of nanoplexes, e.g. polyarginine (Oyarzun-Ampuyero 101 
et al., 2011) and protamine (Umerska et al., 2014a). Protamine is a naturally occurring and 102 
strongly charged cationic protein already used in formulations containing insulin (AHFS Drug 103 
Information, 1989). Protamine (PROT) is rich in arginine and displays a membrane translocation 104 
activity (Reynolds et al., 2005). PROT offers a long history of use and established biological 105 
effects and safety in humans (Reynolds et al., 2005). It has been demonstrated to form 106 
polyelectrolyte complexes with oligonucleotides (Junghans et al., 2000; González Ferreiro et al., 107 
2001) and glycosaminoglycans: hyaluronic acid (HA) (Umerska et al., 2014a) and heparin (Mori 108 
et al., 2010). 109 
The recently described HA/PROT NPs have been shown to successfully encapsulate salmon 110 
calcitonin (sCT) with the association efficiency up to 100% and the advantage of high peptide 111 
loading (10-40% w/w) (Umerska et al., 2014a). However, the release of sCT was relatively quick 112 
as most of the peptide associated with the particles was released within 2-4 hours due to the 113 
weak electrostatic interactions between the species forming the NPs. Thus the strengthening of 114 
intermolecular interactions may decrease the release rate of sCT. Chondroitin sulphate (CHON) 115 
can be considered as a suitable candidate to form polyelectrolyte complexes with PROT and also 116 
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with sCT. CHON have weak (carboxylate) and strong (sulphate) acid residues, in contrast to HA, 117 
which only has carboxylate groups. Moreover, the charge density in CHON molecules is higher 118 
than in HA (Denuziere et al., 1996). Therefore it is anticipated that the electrostatic interactions 119 
between CHON and PROT as well as CHON and a cationic sCT will be stronger compared to 120 
HA-based interactions. Due to its acidic nature CHON is able to produce ionic complexes with 121 
positively charged molecules. Indeed, similarly to HA, CHON has been shown to form 122 
polyelectrolyte complexes with chitosan (Denuziere et al., 1996, Place et al., 2014), 123 
trimethylchitosan (Place et al., 2014), lysozyme (van Damme et al., 1994) and polyethylenimine 124 
(Pathak et al., 2009). 125 
CHON is an abundant glycosaminoglycan found in cartilage, bone and connective mammalian 126 
tissue. It exhibits a wide variety of biological functions and is currently used as an anti-127 
inflammatory, chondroprotective and antirheumatic drug. CHON has been shown to be absorbed 128 
after oral administration in humans as a high molecular weight polysaccharide (Volpi, 2002). sCT, 129 
currently recommended for short term use in Paget’s disease, acute bone loss due to sudden 130 
immobilisation and hypercalcaemia caused by cancer (EMA, 2014),  has also been considered 131 
as a promising candidate to be used in osteoarthritis (Manicourt et al., 2005) and in combined 132 
therapy with alendronate in patients with rheumatoid arthritis (Ozoran et al., 2007). The biological 133 
and pharmacological properties of sCT are therefore complementary to those of CHON. 134 
A combination of CHON with its anti-inflammatory and chondroprotective action and PROT, due 135 
to its membrane-translocating activity, may be interesting from the therapeutic point of view and 136 
such hybrid CHON/PROT NPs may have the potential to form carriers for the oral delivery of 137 
peptides, in particular sCT. Patient compliance was identified as one of the major issues of long-138 
term therapies involving parenteral administration of peptides, hence developing such a delivery 139 
system is of significance (Lee and Sinko, 2000). The low bioavailability of sCT after oral 140 
administration has been attributed to proteolytic enzymatic degradation and low intrinsic intestinal 141 
membrane permeability (Lee and Sinko, 2000), however a correlation between enhancement of 142 
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sCT absorption and mucoadhesion in rats was found by Sakuma et al. (1999, 2002). The 143 
Sakuma’s delivery system comprised NPs with hydrophilic, ionic polymeric chains attached to the 144 
NP surface and sCT incorporated in the NPs non-covalently. These NPs also protected the 145 
peptide against digestive enzymatic degradation in vitro and shielding sCT from pepsin and 146 
trypsin was also observed for polymeric HA/PROT NPs (Umerska et al., 2014a). 147 
Considering the above and that no drug delivery system, especially in the nanoparticulate format, 148 
comprising CHON and PROT has been reported to date, the aims of the current work were to 149 
investigate the conditions of such carrier formation by adopting the previously presented 150 
manufacturing process (Umerska et al., 2012; Umerska et al., 2014a, Umerska et al., 2014b), to 151 
evaluate the conditions of NP formation and their properties as well as to explore the ability of 152 
CHON/PROT NPs to bind and release sCT. Bearing in mind that CHON/PROT NPs are 153 
polyelectrolyte complex NPs, their potential as extended/controlled drug release systems was 154 
also studied and evaluation of suitability of solid-state techniques, as methods supporting the 155 
peptide release studies, was performed.  156 
2 Materials and methods 157 
2.1 Materials 158 
Chondroitin 4-sulfate sodium salt (CHON) and protamine sulphate (PROT, molecular weight of 159 
5.1 kDa; manufacturer’s data) were purchased from Sigma (Ireland). Salmon calcitonin (sCT, 160 
molecular weight 3.4 kDa, freely soluble in water, isoelectric point of 8.86 (Torres-Lugo and 161 
Peppas, 1999) and net charge at pH 7.4 of approximately 3+) was obtained from PolyPeptide 162 
Laboratories (Denmark). CellTiter 96® Non-Radioactive Cell Proliferation Assay was obtained 163 
from Promega Corporation (USA). Other cell culture reagents were provided by Sigma Aldrich 164 
(Ireland). All other reagents, chemicals and solvents were of analytical grade. 165 
The molecular weight of CHON was determined using a gel permeation chromatography system 166 
previously described (Umerska et al., 2012).  Briefly, CHON was dissolved in a mobile phase 167 
composed of 0.2M NaCl and 0.01M NaH2PO4 brought to pH 7.4 with NaOH solution. Pullulan 168 
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standards (PL Polymer Laboratoires, Germany) were used to construct the calibration curve. 169 
Standards and samples were prepared as 1 mg/ml solutions in the mobile phase. 100 µl of the 170 
standard or sample was injected into the Plaquagel-OH mixed 8µm 300 × 7.5 mm column 171 
(Polymer Laboratories Ltd., UK) using a flow rate of 1 ml/min. A Waters 410 refractive index 172 
detector was employed. Data collection and integration were accomplished using CLASS-VP 173 
software (version 6.10) with GPC for Class VP (version 1.02) (Shimadzu, Japan). The weight 174 
average molecular weight (Mw) of CHON was 58.6±0.23 kDa. 175 
2.2 Preparation of CHON/PROT carriers and CHON/PROT/sCT NPs  176 
The CHON solutions with concentrations of 1, 2, 3 or 5 mg/ml as well as the PROT solutions with 177 
concentrations of 0.4-12 mg/ml were prepared in deionised water. NP carriers (NPs without the 178 
cargo) were formed by adding 4 ml of an aqueous PROT solution to 10 ml of a CHON solution at 179 
room temperature under magnetic stirring. The stirring was maintained for 10 minutes to allow 180 
stabilisation of the system. A dispersion of particles was instantaneously obtained upon mixing of 181 
the polymer solutions. As a range of CHON/PROT ratios were used, the NP dispersions that were 182 
formed had different compositions of CHON (equivalent to 0.71 mg/ml, 1.43 mg/ml 2.14 mg/ml or 183 
3.57 mg/ml in the final formulation) and PROT (equivalent to 0.11-3.43 mg/ml in the final 184 
formulation).  185 
NPs containing sCT were formed following the above procedure. An appropriate quantity of the 186 
peptide, resulting in the final sCT concentration in the NP dispersion of 0.5 and 1.0 mg/ml, was 187 
dissolved in the CHON solution prior to mixing with the PROT solution.  188 
2.3 NPs characterisation and stability 189 
2.3.1 Transmittance measurements 190 
The transmittance of the NP dispersions was measured using an UV-1700 PharmaSpec UV-191 
Visible spectrophotometer (Shimadzu) at an operating wavelength of 500 nm in optically 192 
homogenous quartz cuvettes (Hellma, Germany) with a light path of 10 mm (Umerska et al., 193 
2012). 194 
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2.3.2. Dynamic viscosity and quantification of associated in NPs CHON 195 
Dynamic viscosity measurements of CHON and PROT solutions as well as NP dispersions were 196 
carried out with an SV-10 Vibro Viscometer (A&D Company Limited) at 25±0.2 ºC. The instrument 197 
was calibrated using deionised water before measurements and the analysis was done at least 198 
in triplicate for each batch of the liquid sample. The amount of free/unassociated with NPs CHON 199 
was determined from viscosity measurements of continuous phases of NP dispersions. The 200 
viscosity value of pure CHON solution, for a given polymer concentration, was taken as containing 201 
100% free CHON, while the viscosity of water was taken as containing 0% free CHON, since the 202 
viscosity of the continuous phase of a colloidal dispersion compared to that of water can be 203 
correlated with the quantity of free polymer present in the liquid (Umerska et al., 2012). The 204 
amount bound/associated in NPs CHON (expressed as %) was calculated as a difference 205 
between the starting quantity of CHON used in formulation (using the initial CHON concentration) 206 
and the quantity of free/unassociated CHON.   207 
2.3.3 Particle size and zeta potential analysis 208 
The intensity-averaged mean particle size (hydrodynamic particle diameter), polydispersity index 209 
(PDI) and zeta potential (ZP) values of the NPs were determined as previously described by 210 
Umerska et al., (2014b). Samples, in their native dispersions, were placed into folded capillary 211 
cells without dilution. Each analysis was carried out at 25 ºC with the equilibration time set to 5 212 
minutes. The readings were repeated at least three times for each batch and the average values 213 
of at least three batches are presented. The results obtained were corrected for the sample 214 
viscosity measured at described above.  215 
2.4 Salmon calcitonin (sCT) loading studies  216 
2.4.1 Separation of non-associated sCT 217 
Non-associated sCT was separated from the NPs using a combined ultrafiltration-centrifugation 218 
technique (Amicon® Ultra-15, MWCO of 30 kDa, Millipore, USA). A total of 5 ml of sample was 219 
placed in the sample reservoir (donor phase) of the centrifugal filter device and centrifuged for 1 220 
10 
hour at 3,000 rpm (4,537 g). After centrifugation, the volume of the solution in the filtrate vial 221 
(acceptor phase) was measured, and the filtrate was assayed for sCT content via high 222 
performance liquid chromatography (HPLC), as described below. This quantity of sCT was 223 
referred to as the non-associated sCT.  224 
The NP suspension from the sample reservoir was standardized to 5 ml with deionised water. A 225 
total of 0.75 ml of the NP suspension from the sample reservoir was mixed with 0.75 ml of 0.1 226 
mM NaOH (this NaOH concentration was optimised and did not cause sCT degradation) to break 227 
up the NPs and release sCT, and the mixture was centrifuged for 30 minutes at 13,000 rpm 228 
(16,060 g). The supernatant was assayed for sCT content via HPLC, and this portion of the 229 
peptide was referred to as the extracted sCT. The remainder of the dispersion from the sample 230 
reservoir was analysed for particle size, zeta potential and transmittance. The particle size, zeta 231 
potential, transmittance, pH and viscosity of NPs before separation of the non-associated sCT 232 
were also measured. 233 
The association efficiency (AE) and drug loading (DL) were calculated using the following 234 
equations (Umerska et al., 2014b): 235 
 =   ∗ 100%  (Eqn. 1) 236 
where A is the total amount (mass) of the sCT, and B is the mass of the non-associated sCT 237 
 =   ∗ 100%  (Eqn. 2) 238 
where C is the total weight of all components of the NPs (the associated sCT and the mass of 239 
CHON and PROT used for the preparation of NPs). 240 
2.4.2 Colloidal behaviour of CHON/PROT/sCT NPs in different media 241 
Aliquots of 250 µl of sCT-loaded CHON/PROT NPs (CHON conc. 2.1 mg/ml, sCT conc. 1 mg/ml, 242 
CHON/PROT mass mixing ratio (MMR)=6.3) were added to 2.25 ml of the dispersant. The 243 
following dispersants were used:  244 
● phosphate-buffered saline (PBS) pH=7.4 (137 mM NaCl, 2.7 mM KCl, 1.4 mM NaH2PO4, 245 
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1.3 mM Na2HPO4 adjusted to pH 7.4 with NaOH solution), 246 
● PBS pH=5 (137 mM NaCl, 2.7 mM KCl, 1.4 mM NaH2PO4, 1.3 mM Na2HPO4 adjusted to 247 
pH 5 with HCl solution), 248 
● diluted PBS pH=7.4 (1:10 dilution with deionised water of pH 7.4 PBS),  249 
● acetate buffer pH=5 (0.0375M CH3COOH and 0.0643M of CH3COONa pH=5), 250 
● acetate buffer pH=7.4 (0.0375M CH3COOH and 0.0643M of CH3COONa adjusted to pH 251 
7.4 with NaOH solution),  252 
● diluted acetate buffer pH=5 (1:10 dilution with deionised water of pH 5 acetate buffer),  253 
● deionised water  254 
● HCl 0.07M pH=1.2 255 
● Eagle’s Minimal Essential Medium (MEM), pH=7.4 256 
● aqueous NaCl solution with the following concentrations: 0.09%, 0.23%, 0.45%, 0.9% and 257 
1.8% w/v 258 
Samples were incubated at 37 ºC at 100 rpm in a reciprocal shaking water bath (model 25, 259 
Precision Scientific, India). Size and zeta potential measurements (Section 2.3.2) were performed 260 
after 1 hour of incubation. 261 
2.4.3 Release studies  262 
Aliquots of 250 µl of sCT-loaded CHON/PROT NPs (CHON conc. 2.1 mg/ml, sCT conc. 1 mg/ml, 263 
CHON/PROT mass mixing ratio=6.3) were added to 2.25 ml of dispersant. The following 264 
dispersants were used: PBS (pH 5 and 7.4), diluted PBS (pH 7.4), acetate buffer (pH 5 and 7.4), 265 
diluted acetate buffer (pH 5), deionised water and 0.07M HCl (pH 1.2). The samples were 266 
incubated at 37 ºC at 100 rpm in a reciprocal shaking water bath (model 25, Precision Scientific, 267 
India). After 1, 2, 4, 6 and 24 hours, 2.5 ml aliquots were withdrawn, and the released sCT was 268 
separated using the combined ultrafiltration-centrifugation technique as described above. The 269 
samples were centrifuged at 4,500 rpm (6,805 g) for 15 minutes. After centrifugation, the volume 270 
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of the solution from the filtrate vial (acceptor phase) was measured, and the filtrate was assayed 271 
for sCT content by HPLC (released sCT; the HPLC method is described below). The NP 272 
dispersion from the sample reservoir was made up to 2.5 ml with the dispersant and returned to 273 
the water bath to continue the release studies. 274 
The data from the release studies were fitted to the first-order equation:  275 
 = (1 − )  (Eqn. 3) 276 
where W is the amount of the peptide released at time t (based on cumulative release), W∞ is the 277 
amount of the peptide released at infinity and k is the release rate constant (Corrigan et al., 2006).  278 
2.4.4 Quantification of sCT 279 
Analysis of sCT content was performed using an HPLC system as described previously (Umerska 280 
et al., 2014b). Briefly, standard solutions of sCT (1.5–50 µg/ml) were prepared in deionised water, 281 
and 50 µl of the standard or sample was injected into the Jones Chromatography Genesis 4µ C18 282 
150x4.6 mm column. A flow rate of 1 ml/min was employed using a mobile phase composed of 283 
0.116% w/v NaCl, 0.032% v/v trifluoroacetic acid and 34% v/v acetonitrile. The UV detection was 284 
carried out at 215 nm. The sCT peak had a retention time of ~5 min. Data collection and 285 
integration were accomplished using CLASS-VP software (version 6.10, Shimadzu, Japan). 286 
2.5 Solid state characterisation 287 
Solutions of CHON (5 mg/ml) and PROT (12 mg/ml) as well as a range of CHON/PROT NP 288 
dispersions (without sCT) were prepared as described in Section 2.2. The following CHON/PROT 289 
MMRs and CHON concentrations were tested: complex 1 (COM1, MMR=3.1, final CHON 290 
conc.=0.7 mg/ml), complex 2 (COM2, MMR=3.1, final CHON conc.=1.4 mg/ml), complex 3 291 
(COM3, MMR=12.5, final CHON conc.=1.4 mg/ml), complex 4 (COM4, MMR=3.1, final CHON 292 
conc.=2.1 mg/ml), complex 5 (COM5, MMR=5, final CHON conc.=3.6 mg/ml) and complex 6 293 
(COM6, MMR=0.2, final CHON conc.=0.16 mg/ml). In addition, samples of CHON/PROT/sCT 294 
NPs were collected after 6h of release studies (release studies are described in Section 2.4.3). 295 
All liquid samples were freeze dried following the procedure presented by Umerska et al. (2012) 296 
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and analysed by powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC) and 297 
attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) (Paluch et al., 298 
2010, 2013). Briefly, a Miniflex II Desktop X-ray diffractometer Rigaku with a Haskris cooling unit 299 
was employed. The tube output voltage used was 30 kV and tube output current was 15 mA. A 300 
Cu-tube with Ni-filter suppressing Kβ radiation was used. Measurements were taken from 5 to 40 301 
on the 2 theta scale at a step size of 0.05° per second. DSC experiments were performed using 302 
a Mettler Toledo DSC 821e with a refrigerated cooling system LabPlant RP-100. Nitrogen was 303 
used as the purge gas. Aluminium sample holders were sealed with a lid and pierced to provide 304 
three vent holes. Sample weights were approximately 3 mg and measurements were carried out 305 
at a heating rate of 10 °C/min. The unit was calibrated with indium and zinc standards. ATR-FTIR 306 
spectra were recorded on a PerkinElmer Spectrum 1 IR Spectrometer and evaluated using 307 
Spectrum v5.0.1 software. The spectral range was 650–4000 cm−1 and a resolution of 4 cm−1. Six 308 
scans were collected, averaged and normalised to obtain good quality spectra.  309 
2.6 Cell culture and in vitro cytotoxicity studies 310 
Intestinal epithelial cells (Caco-2) were obtained from the European Collection of Cell Cultures. 311 
Cells were cultured as a monolayer in Eagle’s Minimal Essential Medium (MEM) supplemented 312 
with 20% fetal bovine serum (FBS), penicillin (0.006 mg/ml), streptomycin (0.01 mg/ml), 313 
gentamicin (0.005 mg/ml), sodium bicarbonate (2.2 g/l) and sodium pyruvate (0.11 g/l) in a 5% 314 
CO2 and 37 ºC humidified atmosphere (CO2 incubator series 8000DH, ThermoScientific, USA). 315 
Cells were supplied with fresh medium every second day and split after detachment with EDTA-316 
trypsin twice a week. The passage number range was maintained between 20 and 30. 317 
2.6.1 MTS assay 318 
The Caco-2 cells were seeded into flat-bottom 96-well plates in 100 µl of MEM containing 20% of 319 
FBS at a density of 25,000 cells per well and incubated at 37 ºC for 24 hours. The medium was 320 
replaced with 100 µl of the sample dispersed or dissolved in serum-free media. After 72 hours of 321 
incubation, the supernatant was removed from the wells and replaced with serum-free media. An 322 
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amount of 20 µl of MTS reagent prepared according to the manufacturer protocol was added into 323 
each well; in the case of the positive control (0% viability), the media was replaced with a 10% 324 
SDS solution in serum-free media 30 min before the addition of MTS reagent. After 4 hours, the 325 
UV absorbance of the formazan product was measured spectrophotometrically (FLUOstar 326 
Optima microplate reader, BMG Labtech) at 492 nm. The positive control was treated as a blank, 327 
and its absorbance was subtracted from each reading. The cell viability was expressed as the 328 
ratio of the absorbance reading of the cells treated with different samples and that of the negative 329 
control (cells treated with serum-free MEM), which was assumed to have 100% of cell viability. 330 
Experiments were repeated 3 times. 331 
2.7 Statistical analysis 332 
The statistical significance of the differences between samples from in vitro release studies was 333 
determined using one-way analysis of variance (ANOVA) followed by the post-hoc Tukey’s test 334 
using Minitab software. Differences were considered significant at p<0.05. As regards cell culture 335 
studies, statistical differences between groups were determined by Student's t-test. A two-tailed 336 
p-value <0.05 was considered as statistically significant. 337 
3. Results  338 
3.1 CHON/PROT NPs: formation and formulation variables 339 
Depending on CHON/PROT mass mixing ratio (MMR) and the concentration of both 340 
polyelectrolytes, different types of CHON/PROT dispersions, i.e. solution (transmittance above 341 
95%), opalescent (transmittance 85-95%), turbid (transmittance 0.1-85%) dispersion or a phase 342 
separation were observed. Fig. 1 shows the properties of macroscopically homogeneous (i.e. 343 
either having the appearance of a solution or being opalescent or turbid) CHON/PROT 344 
polyelectrolyte complexes dispersed in the form of colloidal particles.  345 
For each concentration of CHON tested the systems containing more PROT (lower CHON/PROT 346 
MMRs) were generally more turbid (Fig. 1A). All dispersions that are included in Fig.1 were 347 
visually homogenous. The phase separation (observed as particle flocculation) occurred at 348 
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CHON/PROT MMRs of 1.0, 1.1, 1.0 and 1.1 for CHON concentrations of 0.7, 1.4, 2.1 and 3.6 349 
mg/ml, respectively.  350 
Fig.1B shows the mean hydrodynamic diameter of CHON/PROT NPs. CHON/PROT NPs had the 351 
size ranging from 78±3 or 78±12 nm (CHON of 1.4 mg/ml, CHON/PROT MMR=3.0 and CHON of 352 
0.7 mg/ml, CHON/PROT MMR=3.2, respectively) to 296±16 nm (CHON of 3.6 mg/ml, 353 
CHON/PROT MMR=1.2). The particle size increased with an increasing amount of PROT in the 354 
formulation (decreasing CHON/PROT MMR). The concentration of CHON was also found to 355 
affect the particle size of CHON/PROT NPs, especially when it increased from 1.4 mg/ml to 2.1 356 
mg/ml.  357 
Fig. 1C presents PDI of CHON/PROT NPs. The PDI values varied from 0.11±0.00 (CHON of 1.4 358 
mg/ml and CHON/PROT MMR=1.4) to 0.43±0.02 (CHON of 3.6 mg/ml and CHON/PROT 359 
MMR=10.6). The CHON/PROT MMR had a considerable influence on the size distribution of NPs. 360 
The higher the amount of PROT in the dispersion (i.e. the lower CHON/PROT MMR), the more 361 
homogenous the size distribution of the particles was. Also, the PDI values generally increased 362 
with the increasing concentration of CHON and decreased with an increase in the particle size. 363 
All physically stable (i.e. non-sedimenting and non-aggregating) dispersions were characterised 364 
by a negative surface charge between -27.6±5.99 mV (CHON of 2.1 mg/ml, CHON/PROT MMR= 365 
1.2) and -63.1±8.59 mV (CHON of 3.6 mg/ml, CHON/PROT MMR=10.6) (Fig. 1D). The surface 366 
charge of CHON/PROT NPs decreased as the CHON/PROT MMR decreased. This decrease 367 
was marginal at high MMRs (approximately 2-20) and more significant at lower MMRs 368 
(approximately 1.2-2).  369 
The efforts to obtain physically stable (for at least 24h) positively charged CHON/PROT 370 
dispersions of NPs were unsuccessful. When CHON solution (0.16 mg/ml) was mixed with PROT 371 
solution (0.7 mg/ml) at CHON/PROT MMR of 0.2, a very homogenously dispersed (PDI of 0.014± 372 
0.010) small (211±6 nm) NPs bearing positive surface charge of 11.6±0.78 mV were obtained 373 
(Fig. 1b, c and d). Aggregation of the positively charged NPs forming larger NPs and later 374 
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microparticles was observed after a few hours of storing the dispersion at room temperature (Fig. 375 
2).  376 
3.2 Formation and characterisation of sCT-loaded CHON/PROT NPs 377 
The success of loading of sCT into CHON/PROT NPs depended on the concentration of CHON 378 
and PROT solutions as well as their MMR (Table 1).  379 
Visually opalescent or turbid dispersions containing NPs characterised by small and 380 
homogenously dispersed particles were obtained for CHON/PROT MMRs of 2 and greater for all 381 
CHON concentrations tested (i.e. 0.7, 1.4 and 2.1 mg/ml). A further increase in PROT 382 
concentration, and thus a decrease in a CHON/PROT MMR, yielded physically unstable systems, 383 
where phase separation and aggregation were observed. As indicated above, in the case of 384 
CHON/PROT NPs without sCT the colloidal size of the dispersion was maintained even at lower 385 
MMRs of 1.2-1.3. It was impossible to completely dissolve sCT at 1 mg/ml in the 0.7 mg/ml CHON 386 
solution. A clear solution was formed either when 1 mg/ml sCT was dissolved in more 387 
concentrated CHON solutions (i.e. 1.4 and 2.1 mg/ml) or when 0.5 mg/ml sCT was dissolved in 388 
the 0.7 mg/ml CHON solution. Generally, the incorporation of sCT into CHON/PROT NPs resulted 389 
in an increased turbidity of the dispersions (Fig. 1 and Table 1). The turbidity increased with a 390 
decrease in a CHON/PROT MMR and an increase in the concentration of CHON and PROT as 391 
well as the concentration of sCT. 392 
The hydrodynamic diameter of the CHON/PROT/sCT NPs particles varied between 60±6 and 393 
245±32 nm (Table 1). Generally, the incorporation of 0.5 or 1.0 mg/ml of sCT did not impact on 394 
the particle size, but in some cases (i.e. when the CHON/PROT MMR was 2.1 and CHON 395 
concentration was 0.7 or 1.4 mg/ml) loading of sCT increased the particle size compared to 396 
CHON/PROT NPs without sCT (by 50 or 90 nm, respectively). Also, incorporation of 0.5 mg/ml 397 
sCT resulted in a decrease in particle size of CHON/PROT MMR=6.4 NPs (0.7 mg/ml CHON) by 398 
30 nm. Formulations with higher CHON/PROT MMRs (4.2-13) were generally characterised by a 399 
very small particle size below or close to 100 nm, while NPs with CHON/PROT MMRs 2-3 usually 400 
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had the particle size of 150-250 nm (Table 1). sCT-loaded CHON/PROT NPs were characterised 401 
by moderate values of PDI (0.23-0.45) and a negative surface charge (Table 1). 402 
Table 1 shows that CHON/PROT NPs had the sCT association efficiency (AE) values between 403 
98.4 and 99.8%. AEs were slightly higher for formulations containing lower amount of PROT and 404 
higher CHON/PROT MMRs. The differences, although statistically significant, were very small 405 
(less than 1.5%). Peptide loading varied between 13.5 and 37.8%. 406 
3.3 Colloidal behaviour of CHON/PROT/sCT NPs in various media 407 
The size of sCT-loaded CHON/PROT MMR=6.3 NPs depended on the composition of the 408 
continuous phase (Table 2). In diluted acetate buffer (diluted AB) or diluted PBS the particle size 409 
was not different compared to that in water, however a decrease in PDI and an increase in surface 410 
charge was observed. The increase in ionic strength of both media (AB with pH=5 and PBS with 411 
pH=7.4) resulted in an increase in particle size by approximately 50 and 120 nm, respectively, in 412 
comparison to the size in water. Even in PBS the hydrodynamic diameter of the particles was not 413 
significantly different from 250 nm. The increase in the ionic strength of the media also increased 414 
the zeta potential and the NPs became more homogenously dispersed (i.e. PDI values 415 
decreased). The change in pH of the media (AB and PBS pH=5 versus pH=7.4) did not influence 416 
the properties of the NPs significantly (Table 2). The properties of NPs in serum-free medium 417 
(pH=7.4) were comparable to those in PBS. Moreover, the properties did not change within 24 418 
hours of storage. In the acidic medium (0.07M HCl) the particle size increased significantly to 230 419 
nm and, similarly to other media, no further change occurred within 24 hours. A decrease in pH 420 
(HCl solution) led to an increase in the zeta potential to -10 mV.  421 
The influence of ionic strength of the properties of NPs was also examined in NaCl aqueous 422 
solutions. The particle size and zeta potential increased, while the PDI decreased, with an 423 
increase in the ionic strength of NaCl solutions.    424 
3.4 In vitro release of sCT 425 
The amount of sCT released after 24 hours into water or diluted acetate buffer from sCT-loaded 426 
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CHON/PROT MMR=6.3 NPs was below 5% (Fig. 3). In the other media (acetate buffer, PBS, 427 
diluted PBS and HCl solution) the release was greater, 4-6% of sCT was released after 1 hour 428 
and 10-12% after 2 hours, however no burst release was observed. In HCl solution and PBS 429 
33±0.1% and 35±1.8% of the initial amount of sCT was released after 24 hours, respectively. sCT 430 
release in acetate buffer was the same at both values of pH, 5 and 7.4, and a similar behaviour 431 
was observed in PBS (data not shown).  432 
3.5 Solid state characterisation 433 
Two amorphous halos, centred at around 12° and 22° 2θ, were visible on each PXRD 434 
diffractograms for CHON and PROT (Fig. 4). The 22° 2θ peak of PROT was more intense than 435 
that at 12° 2θ, however intensity of the two peaks in CHON was comparable. This shows the 436 
amorphous nature of individual polyelectrolytes with the NP carriers (COM1-COM5) also being 437 
disordered. The sample COM6 (MMR=0.2, final CHON conc.=0.16 mg/ml) of the positively 438 
charged NPs showed Bragg peaks at 11.6, 20.8, 29.1, 29.7 and 31.8° 2θ. In relation to the sCT-439 
loaded samples subjected to dissolution studies, only the NPs in water were fully amorphous and 440 
had no single sharp diffraction peaks characteristic of an ordered structure. NPs recovered from 441 
PBS, diluted PBS and HCl solution all contained two crystalline peaks, at 27.3 and 31.8° 2θ, 442 
however the presence of an amorphous halo was apparent. The sample in acetate buffer was 443 
predominantly crystalline, while that in diluted acetate buffer had a faint Bragg peak at 32.0° 2θ. 444 
Results of DSC studies are presented in Fig. 5 and insets show tables with data evaluation. PROT 445 
and COM6 showed a single glass transition (Tg) event each, PROT at around 185 °C, while the 446 
Tg of COM6 was 10 degrees lower. CHON and COM1-COM5 showed broad endotherms of 447 
dehydration at 97 °C (CHON) or 50-59 °C (COM1-COM5) followed by an exotherm with an onset 448 
around 218-232 °C. This exotherm had notably different enthalpies, of around 138 J/g for CHON 449 
and 39-60 J/g for COM1-COM5. Thermograms of sCT-NPs after dissolution had different shapes 450 
depending on the medium used for the studies.  The exotherm was still present in all of them, 451 
however its position and magnitude was dependent on the composition of the dissolution medium. 452 
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The onset temperatures varied between 210 and 232 °C and the peak enthalpies were between 453 
4 and 30 J/g. 454 
ATR-FTIR spectra of CHON, PROT and COM1 (NPs with MMR=3.1, final CHON conc=0.7 mg/ml) 455 
with band assignments and principal peak positions are shown in Fig. 6. The assignment was 456 
done based on studies of Chen et al., (2005); Fajardo et al., (2012); Awotwe-Otoo et al. (2012) 457 
and Bonkovoski et al., (2014). In both polyions one of the most prominent vibrations is that of 458 
amide I. Despite being a sodium salt, the presence of protonated –COOH moiety in CHON was 459 
evident (as a shoulder at app. 1650 cm-1 of the amide I band and as a group at 1411 cm-1). 460 
Symmetric and asymmetric –S=O vibrations were also clear, however they were more intense in 461 
CHON than in PROT. The spectrum of the complex had bands of both components, but position 462 
and intensity of some peaks, such as those of –COOH, amide I and amide II, was different.   463 
3.6 Cytotoxicity of CHON and CHON/PROT NPs 464 
CHON even at a concentration of 5 mg/ml did not exert any toxic effects on Caco-2 cells (125±10 465 
% of viable cells). PROT complexed to CHON was significantly less cytotoxic than the same 466 
amount of PROT dissolved in serum-free medium (Fig. 7). The cytotoxicity of PROT has been 467 
described by Umerska et al., (2014a) and its IC50 was found to be 0.24±0.01 mg/ml. 83±5% of 468 
cells remained alive after 72 hours of exposure to CHON/PROT NPs containing 0.25 mg/ml of 469 
PROT, compared to 61±10% for solution containing an equivalent content of PROT. No cytotoxic 470 
effects were observed after first 1:1 v/v dilution of the NPs with the serum-free medium (98±5% 471 
of viable Caco-2 cells). At this concentration (0.125 mg/ml) of PROT a significant toxic effect was 472 
still observed for PROT dissolved in the medium.  473 
4. Discussion 474 
4.1 CHON/PROT NPs: formation and formulation variables 475 
CHON/PROT NPs were spontaneously formed using mild fabrication conditions, by mixing 476 
aqueous solutions of polyelectrolytes at room temperature. Similar methods were used previously 477 
to obtain other polyelectrolyte complex NPs such as HA/chitosan (Umerska et al., 2012), 478 
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chondroitin/chitosan (Yeh et al., 2011, Place et al., 2014), HA/PROT (Umerska et al., 2014a) and 479 
HA/polyarginine (Oyarzun-Ampuyero et al., 2011). The process of preparation of polyelectrolyte 480 
complex NPs described above does not involve the use of cross-linkers, organic solvents or 481 
surfactants and a homogenisation step is not needed. This is an advantage over the methods 482 
commonly used to fabricate NPs of polyesters, e.g. PLGA, which require the use of organic 483 
solvents, surfactants and sometimes high temperature or homogenisation (des Rieux et al., 484 
2006). 485 
One of the interesting characteristics of polyelectrolytes is their ability to produce stable 486 
interpolymer complexes between oppositely charged species (Dautzenberg, 2000). CHON has 487 
multiple negative charges at physiological pH coming from sulphate and carboxyl groups. Due to 488 
the high arginine content protamines are strongly basic and have isoelectric point around 12, 489 
therefore in all pH conditions tested in this work (pH between 1.2 and 7.4) PROT has a net positive 490 
charge and can be considered as a polycation. Polyion complexation was evident by ATR-FTIR. 491 
First of all, the band at app. 1650 cm-1 of carbonyl moiety of CHON disappeared completely in the 492 
spectrum of complex, either due to complexation or overlap with the amide I group (Fig. 6). Amide 493 
I and II vibrations in CHON and PROT were seen to change positions indicating a change in 494 
intermolecular interactions. The band of –S=O stretching vibrations in the complex was less 495 
intense than in pure CHON, although it did not move. Electrostatic interactions between the 496 
sulphate groups of CHON and the amine moieties of chitosan were seen in the range of 1150–497 
1300 cm−1 by Kaur et al. (2010) and shifts in the sulphate absorptions for carrageenan/PROT 498 
complexes were noted by Dul et.al. (2015). On the other hand, skeletal vibrational modes (–C-O-499 
C- and -S-O-C- groups) of CHON in the complex remained in the same positions inferring that 500 
CHON and PROT interact with each other electrostatically. In summary, CHON/PROT NPs are 501 
formed by electrostatic interactions between negatively charged sulphate and carboxylate groups 502 
of CHON and positively charged amino acid residues in arginine-rich PROT molecules.  503 
It is commonly accepted that polyelectrolyte complex formation is mainly caused by strong 504 
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interactions between oppositely charged polyelectrolytes, whereby the gain in entropy due to the 505 
release of the low molecular counterions, initially bound to polyelectrolytes, plays a decisive part 506 
(Dautzenberg and Jaeger, 2002; Schatz et al., 2004). A similar mechanism (i.e. via electrostatic 507 
interactions) has already been confirmed to be responsible for formation of the complex NPs (e.g. 508 
Umerska et al., 2012, 2014a and 2014b).  509 
Polyelectrolyte complex dispersions may have the appearance of a solution, an opalescent or 510 
turbid system or a two-phase system consisting of precipitated complex and supernatant liquid. 511 
Usually, there is a narrow window of physicochemical conditions where the complexes are formed 512 
and stay in the form of colloidal dispersion (de Kruif et al., 2004). The process of NP formation is 513 
best conducted in diluted solutions in order to prevent macroscopic gelation, which may lead to 514 
bulk hydrogels (Oh et al., 2009). In this work, the concentration of both polyelectrolytes in the final 515 
dispersion was below 1% w/v (0.1-0.7% w/v). HA nanocomplexes described previously were 516 
formed at comparable conditions (0.1-0.2% w/v) (Umerska et al., 2012, 2014a). It was possible 517 
to obtain CHON-based NPs at higher polyanion concentrations (i.e. between 0.3 and 0.7% w/v) 518 
than the HA-based NPs possibly due to the lower molecular weight of CHON (58.6 kDa) and 519 
consequently lower viscosity of its solutions. It was observed however, that at a higher 520 
concentration (i.e. 2.1 mg/ml or 3.6 mg/ml of CHON) the particles were markedly larger and were 521 
characterised by a broader size distribution compared to lower CHON concentrations (0.7 mg/ml 522 
or 1.4 mg/ml), possibly due to more frequent interparticulate interactions resulting from their 523 
increased numbers. 524 
When both polyions are used in equivalent net charge amounts, the particle yield is maximal 525 
(Boddohi et al., 2009). On the other hand, it has been shown that, as a result of charge 526 
neutralisation, aggregation of polyelectrolyte complex NPs occurs and a phase separation takes 527 
place (Boddohi et al., 2009; Umerska et al., 2012). The formation of stable polyelectrolyte complex 528 
NPs requires that the constituent polyelectrolyte solutions are mixed in non-stoichiometric ratios 529 
(Boddohi and Kipper, 2010). The amount of CHON incorporated in NPs is presented in Figure 1S 530 
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and it is clear that the nanocomplexes are stabilised by the excess of the polyanion.  531 
The stability of polyelectrolyte complex NPs depends on the repulsion between similarly charged 532 
particles. Consequently, the net charge of the system must be either sufficiently positive or 533 
negative if the system is to be physically stable. The polyanion/polycation MMRs, which produced 534 
phase separation, were lower for CHON/PROT systems, compared to HA/PROT polyelectrolyte 535 
complexes described previously (Umerska et al., 2014a) (polyanion/polycation MMRs of 1 and 536 
1.4-1.6, respectively). Therefore CHON is capable of neutralising more PROT in the form of 537 
colloidal dispersion compared to HA and/or this reaction is more efficient in CHON/PROT 538 
systems. This may be due to the difference in the density of acidic sites between both molecules. 539 
CHON has a low charge density and contains residues of weak and strong acid groups present 540 
alternately every two monosaccharide, while hyaluronic acid  is a weak polyacid with a charge 541 
density much lower than CHON, since only one charge can be present every two residues in HA 542 
molecules (Denuziere et al., 1996).  543 
The particle size increased with an increasing amount of PROT in the formulation (decreasing 544 
CHON/PROT MMR) due to neutralisation of CHON by the polycation and attainment of a more 545 
compact structure of NPs. A similar tendency was observed for HA/PROT NPs (Umerska et al., 546 
2014a). The magnitude of size of CHON/PROT NPs (between 78 and 296 nm) was similar to 547 
CHON/polyethylenimine NPs (between 92 and 207 nm) (Pathak et al., 2009) and generally 548 
smaller than CHON/chitosan NPs (between 178 and 370 nm (Yeh et al., 2011) or between 230 549 
and 260 nm (Place et al., 2014)) or N,N,N- trimethylchitosan (between 380 and 540 nm (Place et 550 
al., 2014)). Yeh et al., (2011) also observed that at a fixed MMR (of CHON and chitosan) the 551 
particle size increased with increasing polymer concentration, which is in agreement with our 552 
observations.  553 
Zeta potential magnitude is a surrogate marker for the colloidal stability of NPs. The charge 554 
develops as a function of the excess polymer and is controlled by an ordered polyelectrolyte 555 
complex assembly process (Hartig et al., 2007). The negative zeta potential of these NPs is similar 556 
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to those obtained for HA/PROT NPs (Umerska et al., 2014a). NPs with positive zeta potential had 557 
very poor colloidal stability and thus were not regarded as suitable nanocarriers.  558 
CHON/PROT NPs and HA/PROT NPs (Umerska et al., 2014a) differ from chitosan polyelectrolyte 559 
complexes, e.g. HA/chitosan (Boddohi et al., 2009, Umerska et al., 2012), heparin/chitosan 560 
(Boddohi et al., 2009) and chitosan/dextran (Schatz et al., 2004), because the hydrodynamic 561 
diameter of chitosan-based NPs decreases during titration with an oppositely charged 562 
polyelectrolyte, until a secondary aggregation was obtained, preceding irreversible flocculation.  563 
The semi-crystalline nature of the positively charged NPs (COM6, MMR=0.2, final CHON 564 
conc.=0.16 mg/ml) was surprising, considering that the starting polyelectrolyte compounds and 565 
negatively charged NPs were PXRD amorphous (Fig. 4). The peak at 31.8° 2θ can possibly be 566 
ascribed to sodium chloride, however the rest of Bragg peaks did not match the positions of 567 
diffraction peaks of sodium sulphate, anhydrous or hydrates. Sodium sulphate is expected to be 568 
formed as CHON is used as a sodium salt, while PROT as a sulphate salt. Published reports 569 
indicate that polyelectrolyte complexes could be either amorphous, such as chitosan/CHON 570 
(Denuziere et al., 1996), chitosan/HA (Denuziere et al., 1996), poly[(2-dimethylamino) ethyl 571 
methacrylate]/CHON  (Bonkovoski et al., 2014) or crystalline, for instance chitosan/quinoa protein 572 
(Abugoch et al., 2011) and pectin-NH2/CHON (Fajardo et al., 2012).   573 
The thermogram of CHON (Fig. 5) was consistent with that published previously by Jo et al. 574 
(2012). Bonkovoski et al. (2014) stated that CHON thermally degrades around 230 °C, thus the 575 
exothermic event by DSC is of decomposition. CHON complexation to PROT resulted in a change 576 
in hydration properties of the complexes, as evidenced by the shift of the peak of dehydration 577 
endotherm from app. 97 °C to 50-59 °C for the negatively charged NPs and it was absent for 578 
COM6 (positively charged NPs). Furthermore, COM6 had a visible Tg event, appearing at a lower 579 
temperature than that of pure PROT. Complexation of PROT to CHON resulted in a significant 580 
decrease of enthalpy of the exothermic transition, which can be due to the changing strength of 581 
interactions in the complex. A similar observation was made by Wen et al. (2012) for dermatan 582 
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sulphate/alginate polyelectrolyte complexes. Nevertheless, no correlation was discerned between 583 
the thermal parameters of the carriers and formulation variables such as MMR or CHON 584 
concentration.  585 
The poor physical stability of positively charged NPs was evident from kinetic plots (Fig. 2). As 586 
previously presented, this issue with stability was also seen for HA/PROT NPs (Umerska et al., 587 
2014a) and attributed to a large difference in the molecular weight of both components (~35-fold). 588 
Boddohi et al. (2009) stated that if the polyion in excess (PROT) has a much lower molecular 589 
weight than the other polymer (HA in the above example), poor colloidal stability of the NPs is 590 
observed. As the difference in the molecular weight of PROT and CHON is approximately 10-fold, 591 
the same factor might be responsible for the physical instability of the positivity charged NPs. 592 
Moreover, PXRD and DSC analyses of these NPs (COM6) indicated a semi-crystalline structure 593 
of the polyelectrolyte complex formed, in contrast to the amorphous nature of the negatively 594 
charged NPs. Therefore the factors compromising further the colloidal stability is the lowering of 595 
surface energy and a decrease in surface area triggered by repulsion of water from the crystalline 596 
segments (Caldwell et al., 2010).  597 
4.2 Formation and characterisation of sCT-loaded CHON/PROT NPs 598 
The charge of polyelectrolytes is the most important factor for their self-assembly in NPs. The 599 
protein and polymers must bear opposite charge in order to form polyelectrolyte complexes 600 
(Cegnar and Kerč, 2010). The results show that using high concentrations of PROT and low 601 
CHON/PROT MMRs is not advised if very small NPs below 100 nm are to be obtained. 602 
The high association efficiency and drug loading are in agreement with the results obtained for 603 
sCT-loaded polyelectrolyte complex NPs described previously (Umerska et al., 2014a and 604 
Umerska et al., 2014b). Polyelectrolyte complexes have the ability to undergo reactions of 605 
polyelectrolyte substitution and exchange (Kabanov and Kabanov, 1995). Indeed, it has been 606 
suggested that in ternary HA/PROT/sCT complexes the competition occurs between positively 607 
charged PROT and sCT molecules for binding with negatively charged carboxylic groups of HA 608 
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(Umerska et al., 2014b) and the interaction between PROT and HA has been suggested to be 609 
stronger than between sCT and HA. A decrease in AE values from 98 to 85% was observed when 610 
the HA/PROT MMR decreased from 6 to 2 consistent with substitution of small fraction of sCT by 611 
PROT. In similar conditions in CHON/PROT NPs the decrease in AE values, although statistically 612 
significant (p=0.0274), was much smaller (99.7±0.1 and 98.7±0.5% for CHON/PROT MMRs of 6 613 
and 2, respectively). Moreover, binding of sCT by CHON/PROT NPs was significantly higher than 614 
by HA/PROT NPs. Also, the incorporation of sCT into HA/PROT NPs had a more pronounced 615 
impact on their properties (especially the zeta potential) compared to CHON/PROT NPs. This 616 
behaviour may be attributed to the higher charge density of CHON compared to HA. 617 
4.3 The influence of the dispersant on the properties of CHON/PROT/sCT NPs  618 
The properties of polyelectrolyte complex NPs depend on many parameters, also on the 619 
properties of the dispersant such as its ionic strength and pH (Boddohi et al., 2009). It can be 620 
expected that the properties of polyelectrolyte complexes can change depending on the medium, 621 
as polyelectrolyte complexes are self-assembling objects thermodynamically stable under certain 622 
conditions of medium composition, pH and ionic strength (Kabanov and Kabanov, 1995). 623 
The values of zeta potential in all slightly acidic or neutral media were negative and close to -30 624 
mV, therefore indicating a good colloidal stability of the NPs (Table 2). Even at acidic pH of 1.2, 625 
which could be encountered e.g. in stomach, the particles maintained the negative charge. The 626 
decrease of zeta potential from -47 mV in water to -10 mV in HCl solution suggests that the 627 
Coulomb interactions between positively charged sCT and negatively charged CHON become 628 
weaker, but are still present. Indeed, the in vitro release studies showed that more than 65% of 629 
sCT was associated with the particles after 24 hours of incubation at acidic pH.  630 
It is known that two different effects govern the behaviour of polyelectrolyte complexes after a 631 
subsequent change of the ionic strength of the medium, namely secondary aggregation or 632 
dissolution, depending on the nature of the components of the system (Dautzenberg, 2000). In 633 
CHON/PROT NPs a significant increase in particle size was observed, especially in NaCl solution 634 
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and in PBS (where NaCl is the main component). This is similar to the results obtained by 635 
Oyarzun-Ampuyero et al., (2009), who observed an increase in the particle size of  heparin-loaded 636 
chitosan/HA NPs after contact of the NPs with PBS or Hank's Balanced Salt Solution (HBSS) 637 
compared to the particle size in water. However, partial dissolution was observed in PBS for 638 
HA/PROT NPs described previously (Umerska et al., 2014a).  639 
The interactions between oppositely charged macromolecules depend on the strength of their 640 
acidic or basic groups, their charge density and the degree of neutralisation (Denuziere et al., 641 
1996). It is known that weak complexes are formed between polyelectrolytes containing weak 642 
acidic and basic groups, while oppositely charged polymers containing anions and cations of 643 
strong acids and bases generally form very strong polyelectrolyte complexes (Denuziere et al., 644 
1996). CHON, in contrast to HA, also contains strong acid groups (sulphates) and therefore forms 645 
stronger complexes than HA. It is likely that molecules of the dispersant can penetrate the network 646 
of weak nanoplexes easier. This phenomenon appears to dominate in diluted HA/PROT NPs 647 
leading to their dissolution (Umerska et al., 2014a). In stronger and more compact CHON/PROT 648 
complexes the dissociation of the complex as a result of screening of the charges by salt is lower 649 
and the secondary aggregation predominates, which can be observed as the increase in the 650 
particle size or even in the separation of the phases (Table 2).  651 
Interestingly, chloride anions (present both in NaCl solution and in PBS) appeared to exert a 652 
stronger effect on the properties (especially the particle size) of the CHON/PROT/sCT NPs than 653 
acetate. CHON/PROT/sCT NPs dispersed in acetate buffer with the ionic strength of 0.1M were 654 
characterised by significantly smaller particle size compared to NaCl solution with the ionic 655 
strength of 0.075M (150 nm and 210 nm, respectively). It may be due to the fact that in the 656 
Hofmeister series acetate anion is more kosmotropic compared to more chaotropic chloride anion. 657 
The kosmotropes, which are able to induce order by creating hydrogen bonding throughout water, 658 
are hydrated ions and exert stabilising and salting-out effects on proteins and macromolecules. 659 
On the other hand, chaotrops are able to disrupt water structure, destabilise folded proteins and 660 
27 
give rise to salting-in behaviour (Zhang and Cremer, 2006). Alternatively, the decrease in the 661 
hydrodynamic radius of NPs induced by the acetate ions can be through a salting-out effect as 662 
the CHON chains on the exterior of NPs will find themselves in a poorer solvent, while the increase 663 
in the size caused by NaCl can be explained by a partial dissociation and/or dissolution of the 664 
polyelectrolyte complexes.   665 
4.4 In vitro release of sCT 666 
The kinetics of peptide or protein release from ionic hydrogels depends on various structural 667 
parameters of the protein and polyelectrolyte as well as on the environmental conditions inside 668 
the hydrogel (Cooper et al., 2005). The release data (Fig. 3) was fitted to the first order equation, 669 
as no burst phase was observed and confirmed when the data was fitted to the Gallagher-670 
Corrigan model (Gallagher and Corrigan, 2000), and the parameter estimates obtained and 671 
related statistics are summarised in Table 3.  672 
The release rate constant (k) was greatest for the NPs in the acetate buffer but the greatest 673 
amount of sCT released at infinity (W∞) was estimated with PBS. The values of release rate 674 
constant (k) of sCT from CHON/PROT NPs were markedly lower than those of HA-based NPs 675 
(Umerska et al., 2014a) and the k parameter was approximately a 4-fold lower for CHON/PROT 676 
NPs in PBS. Therefore the peptide/NP complex is stronger in CHON-based NPs compared to 677 
HA-based NPs, which is also supported by lower amounts of sCT released from CHON/PROT 678 
NPs. This is in agreement with outcomes of studies of Kamiya and Klibanov (2003) on lysozyme 679 
release from its water-insoluble complexes.  680 
A good linear correlation between the ionic strength of release medium, but not pH, and sCT 681 
released after 24 h (R2=0.83, p=0.007) and the particle size of NPs in the media (R2=0.89, 682 
p=0.003) was found. However, the release rate (k) was not found to be reliant on the ionic strength 683 
of medium. Chen et al., (2007), who examined the release of bovine serum albumin (BSA) and 684 
R6G (Rhodamine 6G) from chitosan/dextran sulphate NPs in PBS with different ionic strength 685 
also observed that the greatest release of both proteins occurred in the release media of a high 686 
28 
ionic strength. Sustained release of BSA and doxorubicin from CHON/chitosan polyelectrolyte 687 
NPs was reported by Yeh et al (2011) and Tsai et al. (2011), respectively, with evidence that BSA 688 
release properties were pH sensitive. Release of sCT from CHON/PROT MMR=4.2 NPs was 689 
comparable to those from CHON/PROT MMR=6.3 (data not shown), it may be concluded that 690 
release of the loaded bioactive from CHON-based NPs is influenced mainly by the peptide 691 
interactions with the polyanion (CHON) and not with the polycation. 692 
As the sCT-loaded sample subjected to dissolution studies in water was fully amorphous and 693 
retained a majority of the loaded sCT, it can be concluded, based on PXRD and DSC data, that 694 
the peptide was molecularly dispersed within the polyelectrolyte complex. NPs recovered from 695 
PBS, diluted PBS and HCl solution had two crystalline peaks characteristic of sodium chloride. 696 
This was expected as PBS contains sodium chloride and in the HCl medium this salt can be 697 
formed from the sodium ion originating from CHON. NPs after dissolution in acetate buffer retain 698 
the buffer salts, showing as anhydrous sodium acetate (Onwudili and Williams, 2010) however, 699 
the sample from diluted acetate buffer was practically fully amorphous (with a very weak peak 700 
32.0° 2θ of either sodium chloride or sodium acetate). Interesting information in relation to the 701 
sCT NPs was obtained from the thermal analysis studies. While the shape of the thermograms 702 
was strongly dependent on the type of medium used, the decomposition exotherm was still 703 
present in the samples (Fig. 5). Upon incorporation of the peptide, the enthalpy further decreased. 704 
Observing that the enthalpy of the exotherm changed when different dissolution media were used, 705 
an attempt was made to correlate this parameter with the amount of sCT remaining in NPs after 706 
6h of dissolution studies. This relationship was found to be statistically significant (p<0.008, 707 
R2=0.827) and could be described by this linear equation (Eqn. 4):  708 
 709 
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#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ℎ$/0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/4 + 82.7 (Eqn. 4) 710 
 711 
This implies that thermal analysis can be a very useful tool when assessing the amount of actives 712 
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released from polyelectrolyte complexes and indeed the thermal decomposition peak might reflect 713 
the strength of intermolecular interactions in such complexes. The amount of sCT not released 714 
from NPs under the conditions of the in vitro experiment indeed remained strongly complexed to 715 
CHON. 716 
4.5 Cytotoxicity of CHON and CHON/PROT NPs 717 
The cytotoxicity of CHON and NPs was examined in Caco-2 cells to assess any potential toxic 718 
interactions with cells. The toxicity of the PROT in Caco-2 cells has already been reported by our 719 
group (Umerska et al., 2014a). The positive charge on the cationic polymers is believed to be a 720 
major cause of their cellular toxicity. These polymers were found to destabilise and ultimately 721 
rupture the cell membrane as a result of strong electrostatic interaction (Pathak et al., 2009). The 722 
neutralisation of PROT by the formation of nanocomplex with HA was shown to reduce the toxicity 723 
of PROT (Umerska et al., 2014a). The toxic effects observed were attributed to the free PROT 724 
rather that by the PROT bound to the polyanion, as the presence of low molecular weight ions in 725 
the medium led to the dissociation of a subset of the HA/PROT nanocomplexes, resulting in 726 
release of PROT molecules. CHON/PROT NPs appear to be less toxic than HA/PROT NPs. The 727 
protective effect of polyanion in CHON/PROT NPs was observed in NPs containing 0.25 mg/ml 728 
PROT, while in HA/PROT NPs the protective effect of HA was observed only at lower 729 
concentration. Because CHON forms stronger electrostatic complexes with PROT than HA, the 730 
amount of PROT released from CHON/PROT complexes is expected to be smaller compared to 731 
HA/PROT complexes, and therefore CHON/PROT exerted less significant toxic effects. 732 
Complexation to CHON has also been reported to significantly decrease the cytotoxicity of 733 
polyethylenimine in HepG2 and HeLa cells (Pathak et al., 2009).  734 
5. Summary and conclusions 735 
A new type of a nanocarrier composed of CHON and PROT has been successfully developed 736 
and characterised. The formation and properties of CHON/PROT NPs depended mainly on the 737 
MMR of polyion components, but also on their concentration. By modulation of formulation 738 
30 
conditions it was possible to obtain small (100 nm and less) NPs with a narrow size distribution 739 
(PDI below 0.25). sCT was very efficiently (approximately 100%) associated with the NPs and 740 
good peptide loading (14-38%) was achieved. Some of the sCT-loaded CHON/PROT NPs were 741 
as small as 60 nm. CHON/PROT NPs were capable of providing extended release of sCT. 742 
CHON/PROT NPs maintained the negative surface charge and more than 65% of sCT was still 743 
associated with the particles after 24 hours of incubation at acidic pH values (pH=1.2). Ionic 744 
strength and composition of the medium were found to have a significant influence on the release 745 
of sCT from CHON/PROT NPs. PXRD was found to provide an insight into the solid state 746 
properties of the nanoplexes and revealed a semi-crystalline nature of the positively charged 747 
system that was linked to its poor colloidal stability. The effectiveness of thermal techniques in 748 
assessing the amount of actives released from polyelectrolyte complexes was demonstrated. As 749 
complexation to CHON markedly reduced the toxic effects exerted on cells by PROT, 750 
CHON/PROT NPs were found to be compatible and well tolerated by Caco-2 cells showing a 751 
considerable promise of these NPs in clinical applications. 752 
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Table 1. Composition and properties association efficiency (AE) and sCT loading of sCT-loaded 1 
CHON/PROT formulations tested. TR - transmittance, MPS – mean particle size, PDI - 2 
polydispersity index, ZP -zeta potential.  3 
Initial 
CHON 
conc. 
(mg/ml) 
CHON/ 
PROT 
MMR 
CHON 
incorp
orated 
in NPs 
(%) 
Initial 
sCT 
conc. 
(mg/ml) 
TR 
(%) 
MPS 
(nm) 
PDI ZP (mV) AE (%) 
sCT 
loading 
(%) 
0.7 2.1 89±8 0.5 71±5 144±10 0.42±0.16 -32.6±3.7 98.7±0.5 32.0±0.15 
0.7 6.4 73±5 0.5 97±2 60±6 0.42±0.03 -42.5±3.8 99.7±0.1 37.8±0.04 
1.4 2.1  92±4 0.5 43±1 195±14 0.35±0.09 -40.0±3.9 98.8±0.3 18.9±0.06 
1.4 4.2 83±3 0.5 92±1 87±6 0.35±0.07 -42.6±12.6 99.6±0.1 22.0±0.02 
1.4 13.0 72±4 0.5 98±1 76±14 0.45±0.04 -44.9±11.8 99.8±0.1 24.5±0.02 
1.4 2.1 95±2 1.0 22±9 168±10 0.27±0.03 -31.3±1.8 98.4±0.3 31.7±0.08 
1.4 4.2 85±4 1.0 83±6 87±4 0.23±0.01 -37.7±1.0 99.5±0.1 36.0±0.03 
2.1 2.1 95±2 0.5 15±3 224±13 0.30±0.01 -46.6±1.3 98.7±0.3 13.5±0.03 
2.1 3.1 90±3 0.5 68±2 154±5 0.29±0.01 -48.6±7.2 99.6±0.1 15.0±0.02 
2.1 6.3 83±3 0.5 92±1 95±7 0.30±0.02 -47.0±9.2 99.8±0.1 16.8±0.02 
2.1 2.1 95±3 1.0 8±1 245±32 0.45±0.18 -39.6±2.5 98.4±0.1 23.7±0.02 
2.1 3.1 91±2 1.0 48±7 161±12 0.28±0.01 -43.2±2.3 99.5±0.1 26.0±0.02 
2.1 6.3 83±3 1.0 85±2 100±9 0.24±0.01 -47.3±5.2 99.7±0.1 28.7±0.02 
  4 
2 
Table 2. Properties of sCT-loaded CHON/PROT NPs (CHON conc. 2.1 mg/ml, sCT conc. 1 mg/ml, 5 
CHON/PROT MMR=6.3): mean particle size (MPS), polydispersity index (PDI) and zeta potential 6 
(ZP) in different media. The samples were prepared as described in Section 2.4.2 and measured 7 
after 1 hour of incubation at 37 °C. AB - acetate buffer, PBS - phosphate buffer saline, HCl - 8 
hydrochloric acid solution pH=1.2, MEM - Eagle’s Minimal Essential Medium. 9 
Medium MPS 
(nm) 
PDI ZP (mV) 
Water 100±9 0.24±0.01 -47.3±5.2 
PBS, pH=7.4 219±17 0.09±0.04 -24.3±4.1 
PBS, pH=5 213±11 0.08±0.01 -22.5±1.8 
PBS, pH=7.4; 1:10 dil. 116±11 0.16±0.02 -33.7±2.2 
AB, pH=5 149±13 0.06±0.03 -29.0±1.0 
AB, pH=7.4 142±9 0.10±0.03 -27.8±1.5 
AB, pH=5; 1:10 dil. 102±11 0.14±0.05 -32.9±5.1 
HCl, pH=1.2 229±26 0.10±0.05 -10.2±1.1 
MEM, pH=7.4 222±7 0.06±0.03 -24.4±1.5 
1.8% NaCl 295±6 0.08±0.02 -19.8±1.2 
0.9% NaCl 242±9 0.08±0.02 -18.4±1.5 
0.45% NaCl 210±5 0.10±0.02 -23.1±2.1 
0.23% NaCl 172±5 0.17±0.04 -22.8±2.3 
0.09% NaCl 111±6 0.18±0.04 -28.9±1.5 
  10 
3 
Table 3. Model parameter estimates for sCT release data fitted to the first-order model (Eqn. 3, 11 
Section 2.4.2), where W∞ is the amount of sCT released at infinity and k is the release rate 12 
constant. The composition of the media is shown in Section 2.4.2. AB - acetate buffer, PBS - 13 
phosphate buffer saline, IS – ionic strength. 14 
Medium k (h-1) W∞ (µg/mg of NPs) 
Goodness of fit 
(R2) 
Water, IS=0.000 0.124±0.054 12.6±4.6 0.9859 
HCl, pH=1.2, IS=0.070 0.221±0.011 94.4±0.8 0.9965 
AB, pH=5, IS=0.070 0.389±0.012 54.3±11.6 0.9962 
AB, pH=5; 1:10 dil., IS=0.007 0.088±0.105 11.6±5.3 0.9972 
PBS, pH=7.4, IS=0.140 0.201±0.030 100.2±3.7 0.9961 
PBS, pH=7.4; 1:10 dil., 
IS=0.014 
0.250±0.001 72.9±0.8 0.9908 
 15 
1 
 1 
Figure 1. Properties of CHON/PROT NPs: A) transmittance, B) mean particle size (MPS), C) 2 
polydispersity index (PDI) and D) zeta potential (ZP). Conditions of analyses are presented in 3 
Sections 2.3.1 and 2.3.3. Lines are for visual guide only.  4 
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Figure 2. Kinetics of change in particle size (PS, filled squares) and polydispersity index (PDI, 6 
empty squares) of positively charged CHON/PROT NPs (PROT of 0.7 mg/ml, CHON of 0.16 7 
mg/ml).  8 
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Figure 3. Cumulative release profiles of sCT from sCT-loaded CHON/PROT NPs (CHON conc. 10 
2.1 mg/ml, sCT conc. 1 mg/ml, CHON/PROT MMR=6.3) into different media. The experiments 11 
were carried out at 37 °C. The composition of the media is shown in Section 2.4.2.  12 
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Figure 4. PXRD patterns of CHON, PROT, CHON/PROT NPs (COM1: MMR=3.1, final CHON 14 
conc.=0.7 mg/ml; COM6: MMR=0.2, final CHON conc.=0.16 mg/ml) as well as sCT-loaded NPs 15 
(CHON conc. 2.1 mg/ml, sCT conc. 1 mg/ml, CHON/PROT MMR=6.3) recovered after 6h of 16 
dissolution studies in various media: deionised water, PBS pH=7.4, diluted (1:10 v/v) PBS, HCl 17 
sol. pH=2, acetate buffer pH=5 and diluted (1:10 v/v) acetate buffer pH=5.  18 
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Figure 5. DSC thermograms of A): CHON, PROT and CHON/PROT NPs (COM1: MMR=3.1, final 21 
CHON conc.=0.7 mg/ml; COM2: MMR=3.1, final CHON conc.=1.4 mg/ml;  COM3: MMR=12.5, 22 
final CHON conc.=1.4 mg/ml; COM4: MMR=3.1, final CHON conc.=2.1 mg/ml; COM5: MMR=5, 23 
final CHON conc.=3.6 mg/ml; COM6: MMR=0.2, final CHON conc.=0.16 mg/ml), B) sCT-loaded 24 
NPs (CHON conc. 2.1 mg/ml, sCT conc. 1 mg/ml, CHON/PROT MMR=6.3) recovered after 6h of 25 
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dissolution studies in various media: deionised water, PBS pH=7.4, diluted (1:10 v/v) PBS, HCl 26 
sol. pH=2, acetate buffer pH=5 and diluted (1:10 v/v) acetate buffer pH=5. Tables present data 27 
evaluation: Tg - glass transition, dH – enthalpy of process.  28 
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 29 
Figure 6. FTIR analysis of CHON, PROT and COM1 (NPs with MMR=3.1, final CHON conc.=0.7 30 
mg/ml). ν – stretching, νs,a – symmetric and asymmetric stretching, νs – symmetric stretching, νa – 31 
asymmetric stretching and δ – bending vibrations. Arg – arginine. Numbers above peaks indicate 32 
the position of principal bands.  33 
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   34 
Figure 7. Viability of Caco-2 cells as measured by MTS assay after 72 h of exposure to 35 
CHON/PROT NPs (CHON/PROT MMR=3.1) and PROT (mean ± S.D., n=3). Statistical analysis: 36 
*p<0.05. 37 
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